GLP-1 Weight Loss Medications Linked to 41% Lower Cancer Risk Than Surgery, Landmark Study Reveals

By 
Dr Amit Kumar Singh
 on 
 • 
5
 min read

A groundbreaking study published in The Lancet’s eClinicalMedicine has found that first-generation GLP-1 receptor agonists (GLP-1RAs), such as liraglutide and exenatide, reduce the risk of obesity-related cancers by 41% compared to bariatric surgery-even after accounting for differences in weight loss. The findings, presented at the European Congress on Obesity (ECO 2025), challenge assumptions about how these medications protect against cancer and highlight their potential beyond metabolic benefits.

Key Findings

  • 41% lower cancer risk: After adjusting for weight loss, GLP-1RAs outperformed bariatric surgery in preventing 13 obesity-related cancers, including breast, colorectal, and pancreatic cancers.
  • 7.5-year study: Analyzed 6,356 patients with obesity and type 2 diabetes, matched 1:1 for age, sex, BMI, and smoking status.
  • Similar cancer rates: Both groups saw ~5.6 cancer cases per 1,000 person-years, despite surgery’s superior weight reduction.
  • Mechanisms beyond weight loss: Anti-inflammatory effects and metabolic improvements are likely drivers of the protective benefits.

Study Design

Researchers from Clalit Health Services (Israel) compared patients treated with GLP-1RAs (≥6 monthly prescriptions of liraglutide, exenatide, or dulaglutide) to those who underwent bariatric surgery between 2010–2018. Over a median 7.5-year follow-up, 298 participants developed obesity-related cancers, with postmenopausal breast cancer (26%), colorectal cancer (16%), and endometrial cancer (15%) most prevalent.

Why It Matters

Obesity and diabetes are linked to 40% of cancers, but this study suggests GLP-1 medications could disrupt that trajectory. “Weight loss alone doesn’t fully explain the anti-cancer benefits,” said lead author Dr. Yael Wolff Sagy. Co-author Dr. Dror Dicker emphasized the role of inflammation reduction, noting, “GLP-1RAs likely act through multiple pathways to suppress tumor growth.” 

Expert Reactions

Professor Naveed Sattar (University of Glasgow), uninvolved in the study, cautioned that observational data cannot prove causation but called the results “intriguing.” Professor Mark Lawler (Queen’s University Belfast) hailed the findings as “transformational,” suggesting GLP-1 drugs could halve obesity-related cancer risk compared to surgery’s one-third reduction.

SheMed welcomes this important research and is committed to keeping our community informed about advances in women’s health and weight management. We’ll continue to share updates on new studies like this, helping you make empowered, evidence-based decisions on your health journey.

Introducing the SheMed Weight Loss Programme

The SheMed Weight Loss Programme is a female-focused, clinically supervised service designed to support women on their weight loss journey with safety and personalisation at its core. Every participant begins with a comprehensive blood test, ensuring the programme is tailored to their unique health needs and that safety is prioritised from the start. SheMed’s approach includes regular clinical oversight, monthly reviews, and ongoing support, including symptom management and educational resources. Members benefit from progress tracking, weekly check-ins, and a supportive community, all aimed at empowering women to achieve lasting, meaningful results.

Women’s Health and SheMed

SheMed’s commitment to advancing women’s health goes beyond weight loss. In December 2024, SheMed launched an active clinical study to explore how GLP-1 weight loss medications may benefit conditions that disproportionately affect women, such as PCOS, endometriosis, and menopause symptoms. This research addresses the significant gap in women’s health studies-currently, only 1% of UK healthcare research funding is dedicated to female-specific conditions. The SheMed study aims to generate actionable insights on how weight loss treatments can improve not just weight, but also broader aspects of women’s health, helping to shape future care and treatment approaches.

References

  • Sagy, Y. W., Dicker, D., et al. (2025). Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer. eClinicalMedicine, 80, 102345. https://doi.org/10.1016/j.eclinm.2025.102345
  • Chiu, C. J., et al. (2025). Tirzepatide and cancer risk in individuals with and without diabetes: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 16, Article 11898313. https://pmc.ncbi.nlm.nih.gov/articles/PMC11898313/

  • Diabetes, Obesity and Metabolism. (2023). Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 25(1), 123–134. https://pubmed.ncbi.nlm.nih.gov/38018310/

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.